Grant Details
Grant Number: |
1R21CA217638-01A1 Interpret this number |
Primary Investigator: |
Scarinci, Isabel |
Organization: |
University Of Alabama At Birmingham |
Project Title: |
Development, Implementation, and Evaluation of a Smoking Cessation Intervention Tailored to Rural Young Adult African American Men: Toward Scalability |
Fiscal Year: |
2018 |
Abstract
Abstract
Despite smoking fewer cigarettes daily, African American (AA) men suffer higher
morbidity and mortality associated with tobacco-related disorders than whites. Our
preliminary data shows that 39.9% of AA men between 19 and 30 years of age who
resided in rural Alabama smoke cigarettes. Although it has been well established that a
combination of pharmacotherapy and advice-oriented counseling and/or cognitive
behavioral interventions are efficacious in promoting smoking cessation across diverse
populations, these evidence-based treatments for tobacco dependence have not proven
to be effective/efficacious (or even accessible) among some subpopulations suffering
disproportionally from tobacco-related morbidity and mortality. The overall goal of this
feasibility study is to make adaptations to these evidence-based approaches, and
develop, implement, and examine the feasibility and scalability of a theory-based,
culturally relevant smoking cessation intervention for young adult AA men in rural
Alabama who smoke cigarettes. Our formative assessments point to a cognitive-
behavioral intervention delivered by a trained Community Health Worker with the support
from an “expert” physician who can deliver the pharmacological component via Skype
through an integrated approach. The proposed study will address the next three steps in
this process: development of the intervention, pretesting, and feasibility. First, we will
develop the intervention with input from a Community Advisory Committee, followed by
an iterative process by which the target audience will be exposed to materials and
messages to provide feedback (pretesting). Once all intervention components are
finalized, we will recruit participants, randomly assign them to intervention/control
groups, pilot test, and evaluate the intervention. The comparison group will be the
Alabama Tobacco Quitline with 8 weeks of Nicotine Replacement Therapy to be
consistent with the pharmacological approach proposed for the intervention. The primary
outcome will be 7-day point prevalence abstinence (defined as no cigarettes in the past
7 days and verified through measurement of exhaled carbon monoxide levels) at 6-
month follow-up. We will also conduct detailed treatment fidelity and scalability
assessments (acceptability, feasibility, potential reach and adoption, alignment with the
strategic context) to inform a full-scale efficacy trial.
Publications
None